linjc16/ctgov huggingface dataset:
A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.

Study Overview
=================
Brief Summary
-----------------
To assess the efficacy and safety of salvage tratment with Gemcitabine and S-1 Combination in metastatic colorectal cancer

Conditions
-----------------
Advanced Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: Gemcitabine/S-1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non resectable colorectal adenocarcinoma. disease progression during or within 6months after treatment with irinotecan and oxaliplatin contaning regimens. estimated life expectancy of more than 3 months. ECOG status 2 or lower Exclusion Criteria: other tumor type than adenoarcinoma. presence or history of CNS metastasis. evidence of gastrointestinal bleeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gemcitabine/ s-1<br> | Drug: Gemcitabine/S-1<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate |  | 1year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 1year | 
| number of participants with adverse events |  | 1year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
S-1, colorectal cancer, gemcitabine
Bladder Endometriosis: Evaluation in MRI of the Involvement of the Posterior Inferior Wall

Study Overview
=================
Brief Summary
-----------------
Evaluate MRI criteria for involvement of the posterior inferior wall of the bladder in patients with endometrial bladder disease.

Detailed Description
-----------------
PURPOSE: to retrospectively evaluate on MRI the local staging with assessment of ureteral orifices extension in bladder endometriosis./ MATERIALS AND METHODS: Institutional review board approval for this study was obtained and waived written informed consent. The MR images of 39 patients operated for bladder endometriosis over a 6 years period in 3 university Lyon hospitals were reviewed. Two experienced readers reported the vesical repletion volume, the largest lesion size, the location and extension of the lesion within the bladder wall, the distance between the ureteral orifices and the lesion when the vesicovaginal wall was involved, the presence of muco-sub mucosal complex edema and the association with external adenomyosis. MR images were compared with surgical and pathological findings. Efficacy parameters were calculated with 95% confidence interval (CI).

Official Title
-----------------
Bladder Endometriosis: Evaluation in MRI of the Involvement of the Posterior Inferior Wall

Conditions
-----------------
Endometrial Bladder Disease

Intervention / Treatment
-----------------
* Other: Magnetic resonance imaging (MRI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient operated for pelvic endometriosis with bladder resection. Performing a preoperative pelvic MRI with at least 2 perpendicular T2 planes Exclusion Criteria: Refusal to use clinical data and exploration acquired Absence of interpretable preoperative pelvic MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Magnetic resonance imaging (MRI)|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of MRI data with intraoperative data and anatomopathology. | A bladder lesion will be retained when a signal abnormality is present on at least two different sectional planes or weights. The topography of the lesion will be related to the vesico-uterine cul-de-sac, its lateralization, its distance from the bladder neck and meatus, its size and its signal. | Through bladder endometriosis surgery |
Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis

Study Overview
=================
Brief Summary
-----------------
The aim of the interventional study is to compare the different treatment modalities in reducing erythema size and rate of resolving phlebitis.

Official Title
-----------------
To Investigate the Effectiveness of Topical Glycerine Sulphate, Hirudoid Cream and Nil Application in Treating Peripheral Cannula Related Phlebitis

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Drug: Glycerine Magnesium sulphate paste
* Drug: Mucopolysaccharide polysulphate
* Other: No application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to the study institution between Dec 2009 and Feb 2010 and observed to develop redness associated with peripheral infusion cannula. Exclusion Criteria: Thrombosis, poor skin condition, and pus seen at the previous puncture.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Glycerine Magnesium Sulphate paste<br> | Drug: Glycerine Magnesium sulphate paste<br>* Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.<br>|
| Active Comparator: Hirudoid cream<br>Topical Mucopolysaccharide polysulphate | Drug: Mucopolysaccharide polysulphate<br>* Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.<br>|
| Experimental: No application<br>Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms. | Other: No application<br>* No application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Erythema size | The incremental percentage change in erythema size | 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to resolve redness | The rate of phlebitis resolution | 5 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
superficial phlebitis, cannula-related vein inflammation, Glycerine magnesium sulphate, Hirudoid cream, Nursing
Blood Collection From Heart Failure Patients to Evaluate for Galectin-3 Measurement Differences Using Various Collection Tubes

Study Overview
=================
Brief Summary
-----------------
Single-site blood collection investigation.

Detailed Description
-----------------
45 Heart Failure patients will be recruited. Patients will provide a one-time blood sample specimen collection. Theses samples will be de-identified and provided for measurement of Galectin-3 on commercial platforms.

Conditions
-----------------
To Measure Galectin-3 in Heart Failure Patients on Commercial Platforms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heart Failure patients New York Heart Association class able to provide (4) collection tube types Subjects > 18 years old All subjects must provide informed consent and associated documentation Exclusion Criteria: Subjects that cannot tolerate blood withdrawal of 4 specimens collection tube tubes (approximately 40 mLs)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Heart Failure patients<br>No interventions for this study. Blood draw provided by patients. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Obtain 45 matched donor serum and plasma samples sets collected from Heart Failure patients for galectin-3 measurements |  | 6 months |
Pregnancy Outcomes After Uterine Cavity Expansion

Study Overview
=================
Brief Summary
-----------------
This study seeks to evaluate pregnancy outcomes following hysteroscopic uterine cavity expansion surgery for patients with dysmorphic uterine cavities and poor reproductive histories. Patients already planning to undergo surgery at the recommendation of their physicians will be recruited for participation.

Detailed Description
-----------------
Any patient scheduled to undergo hysteroscopic expansion of the uterine cavity at RMANJ is eligible to participate in the study. Patients will be approached for consent to participate in the study prior to undergoing surgery. If enrolled, outcomes following surgery will be followed and recorded.

Official Title
-----------------
Pregnancy Outcomes Following Hysteroscopic Expansion of the Uterine Cavity for Patients With Small Cavities and Poor Reproductive Outcomes

Conditions
-----------------
Miscarriage, Uterus Abnormal, Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient scheduled to undergo hysteroscopic expansion of the uterine cavity Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy | presence of a fetal heartbeat at 8 weeks gestation | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in endometrial volume | Increase or decrease in endometrial volume post-operatively as assessed by saline sonography | 1 month | 
| Time to conceive | Time from post-operative visit to conception | 2 years | 
| Chemical pregnancy | Positive pregnancy test | 2 years | 
| Clinical pregnancy | Presence of a gestational sac on ultrasound | 2 years | 
| Pregnancy loss | Miscarriage; either biochemical or clinical pregnancy loss | 2 years | 
| Ectopic pregnancy | Pregnancy outside the uterus | 2 years | 
| Live birth | Delivery of a liveborn infant | 2 years | 
| Obstetrical complications | Any complications including hypertensive diseases, hemorrhage, etc. | 2 years | 
| Gestational age at delivery | in weeks and days | 2 years | 
| Birthweight | in grams | 2 years |
Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients

Study Overview
=================
Brief Summary
-----------------
Chronic kidney disease is a severe medical problem in Taiwan public health issue, which the highest incidence and prevalence rate in the world.Proton pump inhibitors may increase the risk of pneumonia appearance, which were caused by profound irreversible gastric acid suppression. The study purpose was to characterize difference of developing pneumonia in chronic kidney disease of prior use proton pump inhibitors.

Detailed Description
-----------------
The study used data from Taiwan Health Insurance Research Database; the investigators conducted a population-based cohort study in Taiwan. Case consisted of all patients who had a first diagnosis of chronic kidney disease for the period between 1997 and 2008. The investigators utilized the use of Proton pump inhibitor from chronic kidney disease patients.

Official Title
-----------------
Institute of Emergency and Critical Care Medicine , School of Yang-Ming University

Conditions
-----------------
Chronic Kidney Disease, Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic kidney disease Exclusion Criteria: excluded those patients who had ever been diagnosed with CKD before 1997
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| with PPI<br>CKD with PPI use, follow up at least 5 years began PPI use | |
| with or without Pneumonia outcome<br>Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chronic kidney disease ICD-9 |  | 2012-Dec | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proton pump inhibitors, Pneumonia, Retrospective cohort study
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema

Conditions
-----------------
Erythema

Intervention / Treatment
-----------------
* Drug: CD07805/47 Gel 0.5%
* Drug: CD07805/47 Gel Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, who is at least 18 years of age or older at screening visit. Presence of chronic persistent vascular facial erythema for ≥ 3 months by history. A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1. A Patient Self Assessment (PSA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1. Exclusion Criteria: More than 2 facial inflammatory lesions (papules, pustules, and nodules). Presence of areas of significant scaling or crusting on the face. Presence of psoriatic lesions on the face. Presence of any other dermatological condition of the face that, in the opinion of the Investigator, may significantly interfere with the interpretation of the clinical trial results.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CD07805/47 Gel 0.5%<br>active arm | Drug: CD07805/47 Gel 0.5%<br> <br> |
| Placebo Comparator: CD07805/47 Gel Placebo<br>Comparator arm | Drug: CD07805/47 Gel Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite success on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment) | 2-grade improvement on both CEA and PSA at Hours 3, and 6 after Pre-dose (T0)on Day 29 | Day 29 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite improvement on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment) | 1-grade improvement on both CEA and PSA at 30 minutes after pre-dose (T0) on Day 1 | Day 1 |
The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.

Detailed Description
-----------------
Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia. Use Febuxostat to control their serum uric acid for 1 year. To observe the cardiovascular events of patients, and compare and evaluate the changes of heart function, heart construction, serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat treatment.

Official Title
-----------------
The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study

Conditions
-----------------
Disorders Associated With Peritoneal Dialysis, Hyperuricemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Peritoneal dialysis for more than 3 months with hyperuricemia. Exclusion Criteria: Acute hepatopathy or liver dysfunction (Aspartate transaminase and/or alanine aminotransferase exceed 2 times of normal range) Heart failure (stage IV, NYHA), unstable angina, acute stroke Severe lung disease or cancer unable to sign the informed consent form or disagree following-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular events (heart failure, myocardial infarction, unstable angina which need hospitalization，heart surgery, or death caused by cardiovascular disease.) | heart failure, myocardial infarction, unstable angina which need hospitalization，heart surgery, or death caused by cardiovascular disease. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum uric acid | blood test for serum uric acid | 1st month, 2nd month, 3rd month, 6th month, 9th month, 12th month | 
| cardiovascular function (Heart construction and cardiac ejection fraction determined by echocardiography; blood test: cardiac markers including troponin,myoglobin and creatinine kinase, MB isoenzyme (CK-MB), brain natriuretic peptide) | Heart construction and cardiac ejection fraction determined by echocardiography; blood test: cardiac markers including troponin,myoglobin and creatinine kinase, MB isoenzyme (CK-MB), brain natriuretic peptide. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peritoneal dialysis, hyperuricemia, cardiovascular, Febuxostat
Measurement of Renal Function With Iohexol in Subjects Ingesting Carnitine

Study Overview
=================
Brief Summary
-----------------
The investigators will measure renal function in subjects ingesting carnitine to determine if the product alters renal function.

Official Title
-----------------
Measurement of Glomerular Filtration Rate (GFR) Using Iohexol in Healthy Subjects Taking Creatinine Supplements

Conditions
-----------------
Carnitine Ingestion

Intervention / Treatment
-----------------
* Dietary Supplement: Carnitine
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: carnitine ingestion Exclusion Criteria: renal disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Carnitine<br>Participants will be given Creatinine supplements | Dietary Supplement: Carnitine<br>* Carnitine Ingestion<br>|
| Placebo Comparator: Placebo<br>participants will be given creatinine placebo | Dietary Supplement: Placebo<br>* Carnitine placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Iohexol clearance | Iohexol clearance will be measured | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
carnitine, kidney
The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain

Study Overview
=================
Brief Summary
-----------------
Obesity is considered as the epidemic of the century. Central obesity is one of the metabolic syndrome's features. It has been proven that obesity can cause back pain and headaches; thus, there might be a link between chronic pain and the syndrome. The objective of this study is to assess the prevalence of metabolic syndrome in patients suffering from chronic pain.

Detailed Description
-----------------
All patients will answer a questionnaire, their hip circumference will be measured, and their BMI will be calculated (weight/(height)2 ). The patients' blood pressure will be measured. The patients will be asked to bring their blood tests (lipids and glucose).

Official Title
-----------------
The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain

Conditions
-----------------
Pain and Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 that suffer from chronic pain and are being treated at the pain medicine unit Exclusion Criteria: Pregnant women, patients with abdominal wall defects

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic pain and metabolic syndrome